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The present investigation was undertaken to study the effect of β-blockers and exercise training on cardiac structure and
function, respectively, as well as overall functional capacity in a genetic model of sympathetic hyperactivity-induced heart failure
in mice (α2A/α2CArKO). α2A/α2CArKO and their wild-type controls were studied for 2 months, from 3 to 5 months of age. Mice were
randomly assigned to control (N = 45), carvedilol-treated (N = 29) or exercise-trained (N = 33) groups. Eight weeks of carvedilol
treatment (38 mg/kg per day by gavage) or exercise training (swimming sessions of 60 min, 5 days/week) were performed.
Exercise capacity was estimated using a graded treadmill protocol and HR was measured by tail cuff. Fractional shortening was
evaluated by echocardiography. Cardiac structure and gastrocnemius capillary density were evaluated by light microscopy. At
3 months of age, no significant difference in fractional shortening or exercise capacity was observed between wild-type and α2A/
α2CArKO mice. At 5 months of age, all α2A/α2CArKO mice displayed exercise intolerance and baseline tachycardia associated
with reduced fractional shortening and gastrocnemius capillary rarefaction. In addition, α2A/α2CArKO mice presented cardiac
myocyte hypertrophy and ventricular fibrosis. Exercise training and carvedilol similarly improved fractional shortening in α2A/
α2CArKO mice. The effect of exercise training was mainly associated with improved exercise tolerance and increased
gastrocnemius capillary density while β-blocker therapy reduced cardiac myocyte dimension and ventricular collagen to wild-
type control levels. Taken together, these data provide direct evidence for the respective beneficial effects of exercise training
and carvedilol in α2A/α2CArKO mice preventing cardiac dysfunction. The different mechanisms associated with beneficial effects
of exercise training and carvedilol suggest future studies associating both therapies.
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Introduction
Heart failure (HF) is a common endpoint for many
forms of cardiovascular disease and a significant cause of
morbidity and mortality (1). The development of end-stage
HF often involves an initial insult to the myocardium that
reduces cardiac output and leads to a compensatory in-
crease in sympathetic nervous system activity, which ulti-
mately leads to cardiac dysfunction and remodeling (2,3).
In fact, cardiac hypertrophy in HF is associated with poor
prognosis and constitutes an important independent risk
factor for death (4). Thus, therapies that counteract the
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deleterious effect of sympathetic hyperactivity on cardiac
function and structure in HF are promising for the treatment
of HF.
Pharmacological therapy of HF involves the use of β-
blockers that recognizably protect the myocardium from
excessive adrenergic stimulation (5). In fact, we have previ-
ously observed that carvedilol treatment of HF patients
decreases sympathetic activity measured directly by micro-
neurography performed on the peroneal nerve (6). Although
β-blockers are known for their positive impact on cardiac
function and their ability to reverse remodeling
(7), they fail to improve forearm blood flow and overall
functional capacity of HF patients (6). However, when β-
blocker therapy is associated with exercise training there is
an increase in forearm blood flow and exercise capacity (8).
Exercise training is considered to be an adjunctive
therapeutic strategy for HF (9), since it improves exercise
tolerance, endothelial function, and biochemical and struc-
tural parameters of skeletal muscles (10-12). Indeed, exer-
cise training is effective in reducing a number of cardiovas-
cular risk factors (13,14). However, the effects of exercise
training on left ventricular structure and function are not
completely understood. In fact, several studies in humans
and animals have reported contradictory effects (15-19).
In the present study, we used a genetic model of
sympathetic hyperactivity-induced HF in mice to deter-
mine the isolated effect of β-blockers and exercise training
on cardiac structure and function, and overall functional
capacity. It is important to point out that exercise training
and β-blocker treatment were started before mice pre-
sented signs of HF in order to observe the potential pre-
ventive role of both therapies. We hypothesized that both
exercise training and β-blocker treatment would improve
cardiac function in HF mice. However, exercise training
benefits would be related to an improved exercise toler-
ance and skeletal muscle capillarity density while β-blocker
therapy benefits would be associated with reduced ventric-
ular fibrosis and hypertrophy.
Material and Methods
Animal care
Male wild-type (WT) and congenic α2A/α2C-adrenocep-
tor knockout (α2A/α2CArKO) mice with C57Bl6/J genetic
background, 3 to 5 months of age, were studied. At 3
months of age, α2A/α2CArKO mice display preserved car-
diac function with no signs of lung water retention. In
contrast, at 5 months of age, cardiomyopathy is associated
with a modest but significantly increased water retention in
lungs (20), consistent with pulmonary edema. Genotypes
were determined by polymerase chain reaction on genom-
ic DNA obtained from tail biopsies using primers to detect
the intact and disrupted genes.
Mice were maintained in a light- (12-h light cycle) and
temperature- (22°C) controlled environment and were fed
a pellet rodent diet (Nuvital Nutrientes S/A, Brazil) ad
libitum and had free access to water. WT and α2A/α2CArKO
mice were randomly assigned to control (N = 45), exercise-
trained (N = 33) and carvedilol-treated (N = 29) groups.
This study was carried out in accordance with Ethical
Principles of animal research adopted by the Brazilian
College of Animal Experimentation (www.cobea.org.br). In
addition, this study was approved by the University of São
Paulo Ethics Committee (CEP #004).
Procedures and measurements
Drug treatment and exercise training protocol. Drug
treatment consisted of 8 weeks of carvedilol by gavage (38
mg/kg per day; Baldacci S.A., Brazil). The dose of carvedilol
was optimized to achieve comparable heart rate (HR)
levels as observed in the WT control group.
Exercise training consisted of swimming sessions 5
days/week with gradually increased duration up to 60 min,
for 8 weeks in a warmed water (30-32oC) swimming appa-
ratus adapted for mice (21). The training sessions were
performed during the dark part of light cycle of the mice.
This swimming protocol has been characterized as low to
moderate intensity and associated with improved muscle
oxidative capacity and resting bradycardia (21).
Graded treadmill exercise test. Exercise capacity, esti-
mated by total distance run, was evaluated using a graded
treadmill exercise protocol for mice. After being adapted to
treadmill exercises for 1 week (10-min exercise session),
mice were placed in the exercise lane and allowed to
acclimatize for at least 30 min. Exercise began at 6 m/min
with no grade and increased by 3 m/min every 3 min
thereafter until exhaustion. The graded treadmill exercise
test was performed with both WT and α2A/α2CArKO mice
before and after the experimental period.
Cardiovascular measurements. HR was determined
non-invasively using a computerized tail-cuff system (BP
2000 Visitech Systems, USA) described elsewhere (22).
Mice were acclimatized to the apparatus during daily ses-
sions for 6 days, one week before starting the experimental
period. HR measurements were obtained serially in WT
and α2A/α2CArKO mice once a week throughout the 8-week
experiment.
Non-invasive cardiac function was assessed by two-
dimensional guided M-mode echocardiography in halo-
thane-anesthetized WT and α2A/α2CArKO mice, before and
after the experimental period. Briefly, mice were posi-
tioned in the supine position with front paws wide open,
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and an ultrasound transmission gel was applied to the
precordium. Transthoracic echocardiography was per-
formed using an Acuson Sequoia model 512 echocardio-
grapher (Siemens, USA) equipped with a 14-MHz linear
transducer. Left ventricle systolic function was estimated
by fractional shortening as follows: Fractional shortening
(%) = [(LVEDD-LVESD)/LVEDD] x 100 where, LVEDD =
left ventricular end-diastolic dimension, and LVESD = left
ventricular end-systolic dimension.
Structural analysis
Twenty-four hours after the last drug administration or
exercise-training session, all mice were killed and their
tissues harvested. The heart was stopped at diastole (KCl,
14 mM) and dissected to obtain the left ventricle, which
corresponds to the remaining organ upon removal of both
atria and free wall of the right ventricle. For morphometric
analysis, left ventricle samples obtained from the free wall,
at the level of papillary muscle, were fixed in 4% buffered
formalin and embedded in paraffin, cut in 4-µm sections
and subsequently stained with hematoxylin and eosin.
Two randomly selected sections from each animal were
visualized by light microscopy using an objective with a
calibrated magnification (400X). Myocytes with visible nu-
cleus and intact cellular membranes were chosen for di-
ameter determination. The width of an individually isolated
cardiomyocyte displayed on a viewing screen was manu-
ally traced across the middle of the nuclei with a digitizing
pad and determined by a computer-assisted image analy-
sis system (Quantimet 520; Cambridge Instruments, UK).
For each section, approximately 15 visual fields were
analyzed.
Quantification of left ventricular fibrosis was achieved
by Sirius red staining. Two randomly selected sections
from each animal were visualized by light microscopy
using an objective with a calibrated magnification of 200X.
The interstitial collagen area was quantified by a com-
puter-assisted image analysis system (Quantimet 520;
Cambridge Instruments, USA). Approximately 5 visual fields
were analyzed for each animal.
Capillary-to-fiber ratio was quantified in gastrocnemius
muscle after periodic acid-Schiff staining. Two randomly
selected sections from each animal were visualized by
light microscopy using an objective with a calibrated mag-
nification of 400X. The number of capillaries per fiber was
analyzed in a computer-assisted morphometric system
(Leica Quantimet 520, Cambridge Instruments). Approxi-
mately 15 visual fields were analyzed for each animal.
Statistical analysis
Data are reported as means ± SEM. Two-way ANOVA
for repeated measurements with post hoc testing by Tukey
(Statistica software, StatSoft, Inc., USA) was used to com-
pare the effect of treatment (control, exercise-trained and
carvedilol-treated) and genotype (WT and α2A/α2CArKO)
on HR measurements throughout the experimental period.
Two-way ANOVA with post hoc testing by Tukey was used
to compare the effect of treatment (control, exercise-trained
and carvedilol-treated) and genotype (WT and α2A/α2CArKO)
on distance run, capillary density, fractional shortening
and cardiac structure analysis. Statistical significance was
set at P < 0.05.
Results
Effect of exercise training and carvedilol treatment on
exercise tolerance, heart rate and capillary density
Before starting the experiment (at 3 months of age),
α2A/α2CArKO mice presented exercise capacity similar to
WT mice (428 ± 99 vs 425 ± 107 m, respectively). How-
ever, after 8 weeks of experiment (at 5 months of age), α2A/
α2CArKO mice displayed exercise intolerance compared
with age-matched WT mice (Figure 1A). Exercise training
prevented exercise intolerance in α2A/α2CArKO mice, and
increased exercise tolerance in WT mice (Figure 1A). In
contrast, carvedilol treatment had no impact on exercise
tolerance in either WT or α2A/α2CArKO mice. α2A/α2CArKO
mice displayed baseline tachycardia when compared with
age-matched WT mice (Figure 1B). Both exercise training
and carvedilol treatment significantly decreased baseline
HR in α2A/α2CArKO mice reaching WT control levels from
the 5th week of experiment onward (Figure 1B). The mag-
nitude of HR reduction was similar in both trained and
carvedilol-treated α2A/α2CArKO groups. As expected, exer-
cise training and carvedilol treatment also reduced base-
line HR in WT mice.
α2A/α2CArKO mice displayed capillary rarefaction when
compared with age-matched WT mice (Figure 1C). Exer-
cise training significantly prevented capillary rarefaction in
gastrocnemius muscle of α2A/α2CArKO mice, and signifi-
cantly increased the capillary-to-fiber ratio in WT mice.
Carvedilol treatment had no effect on capillary density in
either WT or α2A/α2CArKO mice (Figure 1C).
Effect of exercise training and carvedilol treatment on
fractional shortening and cardiac structure
At the beginning of the experiment (at 3 months of age),
there was no difference between WT and α2A/α2CArKO
mice in fractional shortening (20.9 ± 1.4 vs 18.0 ± 0.5%),
left ventricle diastolic diameter (3.72 ± 0.1 vs 3.60 ± 0.1
mm), and left ventricle posterior wall thickness (0.60 ±
0.001 vs 0.60 ± 0.001 mm). However, after 8 weeks (at 5
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Figure 1. Effect of exercise training and carvedilol administration
on exercise capacity measured as maximal distance run (A),
heart rate (B) and capillary-to-fiber ratio in gastrocnemius muscle
(C) evaluated in wild-type (open columns, WT) and α2A/α2CArKO
(filled columns, ArKO) mice. The exercise training significantly
improved distance run and capillary-to-fiber ratio while it de-
creased heart rate in α2A/α2CArKO mice. In contrast, carvedilol
treatment had no effect on exercise capacity and capillary den-
sity, but reduced baseline heart rate in α2A/α2CArKO mice. As
expected, trained WT mice displayed resting bradycardia and
increased exercise capacity and capillary density. The number
in parentheses indicate the number of mice in each group. Data
are reported as means ± SEM. *P < 0.05 compared to WT
control group; **P < 0.05 compared to respective control group;
+P < 0.05 compared to respective control group from the 4th
week to the end of experimental period.
Figure 2. Effect of exercise training and carvedilol administration
on fractional shortening used as an index of systolic function (A),
cardiac myocyte cross-sectional diameter (B) and cardiac col-
lagen volume fraction (C) evaluated in wild-type (open columns,
WT) and α2A/α2CArKO (filled columns, ArKO) mice. The exer-
cise training and carvedilol treatment significantly increased frac-
tional shortening in α2A/α2CArKO mice. However, only carvedilol
treatment prevented cardiac remodeling by reducing cardiac
myocyte cross-sectional diameter and collagen volume fraction
in α2A/α2CArKO mice. The number in parentheses indicate the
number of mice in each group. Data are reported as means ±
SEM. *P < 0.05 compared to WT control group; +P < 0.05
compared to respective control group.
months of age), α2A/α2CArKO mice displayed systolic dys-
function when compared with age-matched WT mice (Fig-
ure 2A) and a trend toward increased left ventricle diastolic
diameter (3.80 ± 0.07 vs 3.92 ± 0.03 mm, P = 0.08). Both
exercise training and carvedilol treatment prevented the
systolic dysfunction in α2A/α2CArKO mice by increasing
fractional shortening towards WT mice values (Figure 2A).
In addition, while exercise training significantly increased
fractional shortening in WT mice, carvedilol treatment had
no impact on cardiac contractility (Figure 2A).
Quantitative morphometric analysis showed that car-
diac myocyte cross-sectional diameter was significantly
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greater in α2A/α2CArKO mice compared with WT control
mice (Figure 2B). Exercise training had no effect on car-
diac myocyte cross-sectional diameter in α2A/α2CArKO mice
but increased it in WT mice. Carvedilol significantly re-
duced cardiac myocyte width in α2A/α2CArKO mice. The
reduction of cardiac myocyte cross-sectional diameter in
carvedilol-treated α2A/α2CArKO mice was so remarkable
that it reached WT control mice levels (Figure 2B).
Increased cardiac myocyte cross-sectional diameter in
α2A/α2CArKO mice was paralleled by ventricular fibrosis,
represented by an increase of 45% in cardiac collagen
volume fraction of α2A/α2CArKO mice compared with WT
control mice (Figure 2C). Exercise training did not change
cardiac collagen volume fraction in either WT or α2A/
α2CArKO mice. In contrast, carvedilol treatment significant-
ly reduced ventricular fibrosis in α2A/α2CArKO mice, but
cardiac collagen volume fraction of carvedilol-treated WT
mice remained unchanged (Figure 2C).
Discussion
The main findings of the present study were that exercise
training and β-blocker therapy improved ventricular function
of HF mice similarly. However, the effect of exercise training
was mainly associated with improved exercise tolerance
and skeletal muscle capillary density while β-blocker thera-
py had a greater impact on cardiac structure.
Exercise training is emerging as an adjuvant non-
pharmacological therapy for HF (9) and the benefits of
exercise training on HF are related to improved function of
both cardiac and skeletal muscles (10-12,23). In the pres-
ent investigation, we observed improved fractional short-
ening paralleled by an increased gastrocnemius capillary
density in exercise-trained α2A/α2CArKO mice, which ulti-
mately led to improved exercise tolerance. The importance
of these results is striking because exercise intolerance is
associated with a poor prognosis and reduced quality of
life in HF patients (24). Indeed, an unacceptable burden of
disability and unrelieved symptoms still remain even in
optimally medically treated HF patients (25,26).
The mechanisms underlying the improved cardiac func-
tion and gastrocnemius capillary density in exercise-trained
α2A/α2CArKO mice were not investigated in this study, but
we have previously demonstrated an improved cardiac
myocyte Ca2+ handling after exercise training in α2A/
α2CArKO mice (27,28). Indeed, increased expression of
vascular growth factors seems to be involved in angiogen-
esis induced by exercise training (29).
The effects of exercise training on left ventricular re-
modeling in HF are under investigation (15). Exercise
training had no detectable impact on left ventricular fibro-
sis of α2A/α2CArKO mice. In fact, previous studies demon-
strated little effect of exercise training in total cardiac
collagen fraction (30). Likewise, exercise training did not
change the increased cardiac myocyte width of α2A/α2CArKO
mice. However, we cannot exclude the possibility that
swimming training might preclude pathological hypertro-
phy, since it induces physiological remodeling that is asso-
ciated with improved cardiac function. In fact, as we ob-
served in WT mice, swimming exercise training led to a
physiological hypertrophy, which we showed previously to
be associated with beneficial cardiac effects (21).
In contrast to exercise training, carvedilol treatment
had no effect on gastrocnemius capillary density and exer-
cise tolerance in α2A/α2CArKO mice. This response was
somehow expected, since carvedilol is a non-selective β-
blocker with transient α1-adrenoceptor blockade, which
could reduce skeletal muscle vasodilatation and preclude
improvement in exercise tolerance.
The benefits of carvedilol were mainly due to its effect
on cardiac function and structure. In fact β-blockers yield
impressive benefits on cardiac contractility of patients with
chronic heart failure (17). In the present study, we ob-
served an increased fractional shortening in carvedilol-
treated α2A/α2CArKO mice associated with reduced left
ventricular fibrosis and cardiac myocyte hypertrophy. These
observations suggest that carvedilol prevents cardiac re-
modeling in α2A/α2CArKO mice. The mechanisms involved
in reduced cardiac fibrosis and hypertrophy of carvedilol-
treated α2A/α2CArKO mice were not examined in the pres-
ent investigation; however, reduced cardiac angiotensin II
levels might be involved. In fact, we have recently demon-
strated that α2A/α2CArKO mice display increased cardiac
angiotensin II levels associated with ventricular fibrosis
reversed partially by losartan treatment (20).
The present results demonstrate that both exercise train-
ing and carvedilol therapy improve, to the same extent, the
ventricular function in a genetic model of sympathetic hyper-
activity-induced heart failure in mice. However, while the
benefits of exercise training are mainly associated with
increased aerobic capacity and capillary density of skeletal
muscle, carvedilol benefits were mainly due to its effect on
cardiac structure. These results indicate that studies are
needed to determine the efficacy of exercise training associ-
ated with β-blockers for treatment of heart failure therapy.
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